Prostaglandin F2α FP receptor inhibitor reduces demyelination and motor dysfunction in a cuprizone-induced multiple sclerosis mouse model

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 91, Issue 5, 2014, Pages 175-182

  Iwasa, K ^a   Yamamoto, S ^a   Takahashi, M ^a   Suzuki, S ^a   Yagishita, S ^a   Awaji, T ^a   Maruyama, K ^a   Yoshikawa, K ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cuprizone (CPZ); Demyelination; Multiple sclerosis (MS); Neuroinflammation; Prostaglandin F2 receptor (FP)

Indexed keywords

AL 8810; CLOPROSTENOL; CUPRIZONE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; LATANOPROST; MYELIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN F2 ALPHA RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; TRAVOPROST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN H2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY EQUILIBRIUM; CELL ACTIVATION; CONTROLLED STUDY; CORPUS CALLOSUM; DEMYELINATION; DISEASE MODEL; DRUG DOSE COMPARISON; EMBRYO; GLIA CELL; LOCOMOTION; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; ROTAROD TEST; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DEMYELINATING DISEASE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; MYELIN SHEATH; OLIGODENDROGLIA; PATHOLOGY;

ANIMALS; CORPUS CALLOSUM; CUPRIZONE; DEMYELINATING DISEASES; DINOPROST; DISEASE MODELS, ANIMAL; HUMANS; MICE; MOTOR ACTIVITY; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; PROSTAGLANDIN H2; RECEPTORS, PROSTAGLANDIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908139997     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2014.08.004     Document Type: Article

References (57)

1. Stangel M. Neurodegeneration and neuroprotection in multiple sclerosis. Curr. Pharm. Des. 2012, 18:4471-4474.
2. Bramow S., Frischer J.M., Lassmann H., et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010, 133:2983-2998.
3. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999, 122(Pt 12):2279-2295.
4. Torkildsen O., Brunborg L.A., Myhr K.M., Bo L. The cuprizone model for demyelination. Acta Neurol. Scand. Suppl. 2008, 188:72-76.
5. Benardais K., Kotsiari A., Skuljec J., et al. Cuprizone [bis(cyclohexylidenehydrazide)] is selectively toxic for mature oligodendrocytes. Neurotox. Res. 2013, 24:244-250.
6. Matsushima G.K., Morell P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol. 2001, 11:107-116.
7. Farooqui M., Li Y., Rogers T., et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br. J. Cancer 2007, 97:1523-1531.
8. Rose J.W., Hill K.E., Watt H.E., Carlson N.G. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J. Neuroimmunol. 2004, 149:40-49.
9. Dore-Duffy P., Donaldson J.O., Koff T., Longo M., Perry W. Prostaglandin release in multiple sclerosis: correlation with disease activity. Neurology 1986, 36:1587-1590.
10. Dore-Duffy P., Ho S.Y., Donovan C. Cerebrospinal fluid eicosanoid levels: endogenous PGD2 and LTC4 synthesis by antigen-presenting cells that migrate to the central nervous system. Neurology 1991, 41:322-324.
11. Palumbo S., Toscano C.D., Parente L., Weigert R., Bosetti F. Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85:29-35.
12. Palumbo S., Toscano C.D., Parente L., Weigert R., Bosetti F. The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination. J. Neurochem. 2012, 121:418-427.
13. Yoshikawa K., Kita Y., Kishimoto K., Shimizu T. Profiling of eicosanoid production in the rat hippocampus during kainic acid-induced seizure: dual phase regulation and differential involvement of COX-1 and COX-2. J. Biol. Chem. 2006, 281:14663-14669.
14. Dore-Duffy P., Balabanov R., Beaumont T., Katar M. The CNS pericyte response to low oxygen: early synthesis of cyclopentenone prostaglandins of the J-series. Microvasc. Res. 2005, 69:79-88.
15. Moriuchi H., Koda N., Okuda-Ashitaka E., et al. Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily. J. Biol. Chem. 2008, 283:792-801.
16. Yoshikawa K., Takei S., Hasegawa-Ishii S., et al. Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system. Brain Res. 2011, 1367:22-32.
17. Yoshikawa K., Palumbo S., Toscano C.D., Bosetti F. Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage. Prostaglandins Leukot. Essent. Fatty Acids 2011, 85:43-52.
18. Taylor L.C., Puranam K., Gilmore W., Ting J.P., Matsushima G.K. 17beta-estradiol protects male mice from cuprizone-induced demyelination and oligodendrocyte loss. Neurobiol. Dis. 2010, 39:127-137.
19. Li J., Ramenaden E.R., Peng J., Koito H., Volpe J.J., Rosenberg P.A. Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J. Neurosci. 2008, 28:5321-5330.
20. Chen Y., Balasubramaniyan V., Peng J., et al. Isolation and culture of rat and mouse oligodendrocyte precursor cells. Nat. Protoc. 2007, 2:1044-1051.
21. Li J., Baud O., Vartanian T., Volpe J.J., Rosenberg P.A. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. USA 2005, 102:9936-9941.
22. Steelman A.J., Thompson J.P., Li J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication. Neurosci. Res. 2012, 72:32-42.
23. Saleem S., Ahmad A.S., Maruyama T., Narumiya S., Dore S. PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox. Res. 2009, 15:62-70.
24. Piekorz R.P., Gingras S., Hoffmeyer A., Ihle J.N., Weinstein Y. Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20alpha-hydroxysteroid dehydrogenase. Mol. Endocrinol. 2005, 19:431-440.
25. Hellberg M.R., Sallee V.L., McLaughlin M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J. Ocul. Pharmacol. Ther. 2001, 17:421-432.
26. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008, 1193:153-161.
27. Kim Y.T., Moon S.K., Maruyama T., Narumiya S., Dore S. Prostaglandin FP receptor inhibitor reduces ischemic brain damage and neurotoxicity. Neurobiol. Dis. 2012, 48:58-65.
28. Liu L., Belkadi A., Darnall L., Hu T., et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
29. Blakemore W.F. Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone. J. Neurol. Sci. 1973, 20:73-83.
30. Franco-Pons N., Torrente M., Colomina M.T., Vilella E. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol. Lett. 2007, 169:205-213.
31. Kitanaka J., Hashimoto H., Gotoh M., et al. Expression pattern of messenger RNAs for prostanoid receptors in glial cell cultures. Brain Res. 1996, 707:282-287.
32. Liang Y., Li C., Guzman V.M., et al. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem. 2003, 278:27267-27277.
33. Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice. J. Mol. Med. (Berl) 2009, 87:1015-1022.
34. Besancon E., Guo S., Lok J., Tymianski M., Lo E.H. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol. Sci. 2008, 29:268-275.
35. Skripuletz T., Hackstette D., Bauer K., et al. Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination. Brain 2013, 136:147-167.
36. Lassmann H. Mechanisms of white matter damage in multiple sclerosis. Glia 2014.
37. Nair A., Frederick T.J., Miller S.D. Astrocytes in multiple sclerosis: a product of their environment. Cell. Mol. Life Sci. 2008, 65:2702-2720.
38. Holley J.E., Gveric D., Newcombe J., Cuzner M.L., Gutowski N.J. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol. Appl. Neurobiol. 2003, 29:434-444.
39. Smith M.E., Eng L.F. Glial fibrillary acidic protein in chronic relapsing experimental allergic encephalomyelitis in SJL/J mice. J. Neurosci. Res. 1987, 18:203-208.
40. Axelsson M., Malmestrom C., Nilsson S., Haghighi S., Rosengren L., Lycke J. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J. Neurol. 2011, 258:882-888.
41. Glabinski A.R., Tani M., Strieter R.M., Tuohy V.K., Ransohoff R.M. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 1997, 150:617-630.
42. Ambrosini E., Remoli M.E., Giacomini E., et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 2005, 64:706-715.
43. Fok-Seang J., Smith-Thomas L.C., Meiners S., et al. An analysis of astrocytic cell lines with different abilities to promote axon growth. Brain Res. 1995, 689:207-223.
44. Fawcett J.W., Housden E., Smith-Thomas L., Meyer R.L. The growth of axons in three-dimensional astrocyte cultures. Dev. Biol. 1989, 135:449-458.
45. McKeon R.J., Hoke A., Silver J. Injury-induced proteoglycans inhibit the potential for laminin-mediated axon growth on astrocytic scars. Exp. Neurol. 1995, 136:32-43.
46. McKeon R.J., Jurynec M.J., Buck C.R. The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci. 1999, 19:10778-10788.
47. Sobel R.A. The extracellular matrix in multiple sclerosis: an update. Braz. J. Med. Biol. Res. 2001, 34:603-609.
48. Xu W., Chou C.L., Israel D.D., Hutchinson A.J., Regan J.W. PGF(2alpha) stimulates FP prostanoid receptor mediated crosstalk between Ras/Raf signaling and Tcf transcriptional activation. Biochem. Biophys. Res. Commun. 2009, 381:625-629.
49. Taylor D.L., Pirianov G., Holland S., et al. Attenuation of proliferation in oligodendrocyte precursor cells by activated microglia. J. Neurosci. Res. 2010, 88:1632-1644.
50. Howell O.W., Rundle J.L., Garg A., Komada M., Brophy P.J., Reynolds R. Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:1017-1033.
51. Rasmussen S., Wang Y., Kivisakk P., et al. Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis. Brain 2007, 130:2816-2829.
52. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6:67-70.
53. Fu Y., Sun W., Shi Y., Shi R., Cheng J.X. Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction. PLoS One 2009, 4:e6705.
54. Raivich G., Bohatschek M., Kloss C.U., Werner A., Jones L.L., Kreutzberg G.W. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Brain Res. Rev. 1999, 30:77-105.
55. Yoshikawa K., Kita Y., Furukawa A., et al. Excitotoxicity-induced immediate surge in hippocampal prostanoid production has latent effects that promote chronic progressive neuronal death. Prostaglandins Leukot. Essent. Fatty Acids 2013, 88:373-381.
56. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991, 325:467-472.
57. Caminero A., Comabella M., Montalban X. Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story. J. Neuroimmunol. 2011, 234:1-6.